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Chnical and Laboratory Study of Sickle Cell/p-Thalassemia 
Koichi Maeda, MD,* Ellis J. Van Slyck, MD,^ and Robert C. Hawley, MD' 
We have studied 39 patients doubly heterozygous for sickle cell/^-thalassemia, 12 with sickle cell/^"-
thalassemia and 27 with sickle cell/^'''-thalassemia. Generally, sickle cell/^''-thalassemia is 
considered more severe than sickle cell/^'''-thalassemia. In our study, however clinical complications 
in the group with sickle cell/^'^-thalassemia were seen almost as frequently as in the group with sickle 
cell/^"-thalassemia. A wide variety of clinical manifestations were seen in both groups of patients. 
(Henry FordHosp MedJ 1986;34:282-4) 
T he double heterozygous condition, sickle cell/p-thalassemia, is seen in whites (predominantly Greeks and 
Italians) in the Mediterranean area of southern Europe, and 
mainly in blacks in the United States (1-6). The disease is known 
to manifest a variety of clinical symptoms, particularly vaso-
occlusive crises as well as other, more chronic complications 
noted later Clinically, the cases may range from mild to severe, 
the latter resembling sickle cell anemia (SS). Sickle cell/|3-
thalassemia has been subdivided into 1) sickle cell/p"'"-
thalassemia in which there is impaired but still significant 
p-chain synthesis, and 2) sickle cell/p'^ -thalassemia in which 
there is no 3-chain production. The former condition is more 
common in blacks and is considered clinically milder than the 
latter condition (4,6,7). However, the clinical reports regarding 
these two subgroups are relatively scarce. Furthermore, in our 
practice we have seen patients with sickle cell/|3'^ -thalassemia 
suffering from several complications even though it is consid-
ered a milder disease. Our experience with both subtypes of 
sickle cell/p-thalassemia has been fairly extensive and is the 
basis for this report, which compares the two subtypes with re-
spect to clinical and hematologic manifestations. 
from double heterozygocity for hemoglobin S and hereditary 
persistence of fetal hemoglobin on clinical grounds as well as by 
the presence of microcytosis and elevated hemoglobin A, levels. 
Sickle cell/3"-thalassemia was differentiated from double het-
erozygocity for hemoglobin S and hemoglobin Lepore by acid 
citrate agar electrophoresis. 
All the patients' charts were reviewed. Complete blood counts 
were determined by a Coulter Model S and S Plus electronic cell 
counters. Hemoglobin analysis was done by cellulose acetate 
electrophoresis using TRIS-EDTA acetate buffer at pH 9.2 and 
citrate agar electrophoresis with sodium citric acid buffer at pH 
6.2. Hemoglobin F was also measured by alkaline denaturation. 
Hemoglobin A, was determined by column chromatography. 
Student's t test and the Fisher exact test were used for com-
parison of the data. 
Results 
The patients' ages ranged from 1 to 81 years, with a mean of 
28 years. Twelve patients were younger than 18 years of age. Of 
the 39 patients, 22 were women and 17 were men. There were 36 
blacks and three whites. 
Materials and Methods 
Thirty-nine patients with sickle cell/p-thalassemia were seen 
at Henry Ford Hospital during the past ten years. 
In general, patients with microcytic red cells, a predominance 
of hemoglobin S, no hemoglobin A, variably increased hemo-
globin AJ, and variably increased hemoglobin F were consid-
ered to have sickle cell/p°-thalassemia. Patients with microcytic 
red cells, a predominance of hemoglobin S, a minor component 
of hemoglobin A (in the absence of recent blood transfusion), 
variably increased hemoglobin A^, and variably increased 
hemoglobin F were considered to have sickle cell/P"'"-
thalassemia. Sickle cell/p"-thalassemia was distinguished from 
sickle cell anemia by the presence of microcytosis and elevated 
hemoglobin A, levels. In some cases confirmation was obtained 
by family studies. Sickle cell/3°-thalassemia was distinguished 
Hematologic data 
The hemoglobin ranged from 5.7 to 15.1 g/dL, with a mean of 
10.5 g/dL. The mean corpuscular volume ranged from 63 to 
80.7 U \ with a mean of 72.3 U^. The average mean corpuscular 
hemoglobin concentration was 32.6%. The reticulocyte count 
was determined in 26 patients; the count ranged from 0.8% to 
30.5%, and the mean was 6.4%. 
Twelve patients had no hemoglobin A and were considered to 
have sickle cell/p"-thalassemia. The remaining 27 patients had 
hemoglobin A ranging from 8.7% to 26.8%, with a mean of 
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Table 1 
Hematological Data 
Sickle Cell/3» Thalassemia Sickle Cell/(3+ -Thalassemia 
No. Mean Range No. Mean Range P-value 
Hemoglobin (g/dL) 12 8.7 5.7-10.9 27 11.3 8.4-15.1 0.01 
Reticulocyte (%) 10 8.7 2.0-30.5 16 4.9 0.8-25.0 0.01 
Hemoglobin S (%) 12 83.7 74.0-95.7 27 67.8 46.2-83.4 0.01 
Hemoglobin A (%) 12 0 0 27 18.8 8.7-26.8 
— 
Hemoglobin F (%) 12 11.7 0.2-22.3 27 8.3 0.8-27.7 NS 
Hemoglobin A, (%) 12 5.0 3.4-6.9 27 4.9 2.1-7.2 NS 
MCV (U5) 12 72.2 27 69.6 NS 
MCHC(%) 12 31.8 27 31.4 NS 
Bilirubin (mg%) 10 2.1 0.7-3.1 17 1.7 0.3-11.0 — 
NS = not significant. 
18.8%. The hemoglobin A, ranged from 2.1% to 7.2%, with a 
mean of 4.9%. The hemoglobin F ranged from 0.2% to 27.7%, 
with a mean of 9.3%. The hemoglobin S ranged from 46.2% to 
95.7%, with a mean of 72.7%. 
Total bilimbin was available in 27 patients. It ranged from 0.3 
to 11.0 mg%, with a mean of 1.9 mg%. 
Clinical findings 
Thirty-two patients had painful episodes, seven had 
hepatomegaly, one had a leg ulcer, 18 had joint pain, four had 
cardiomegaly, and four had avascular necrosis of bone. Three of 
the four patients with avascular necrosis of bone had involve-
ment of the hip. Fifteen patients had splenomegaly, and two 
patients had undergone splenectomy. 
Other complications observed included two patients with dac-
tylitis (periostitis of the small bones of the hands and feet), three 
patients with thrombophlebitis of the leg, three patients with 
cholelithiasis requiring cholecystectomy, and three patients 
with retinal hemorrhages and detachments. In addition, spo-
radic pneumonia, upper respiratory infection, and urinary tract 
infection were observed in some patients. Two patients with 
sickle cell/p°-thalassemia died at 33 and 38 years of age, respec-
tively. The death of the 33-year-old, a black woman, was due to 
thrombophlebitis and congestive heart failure associated with 
severe chronic anemia requiring multiple transfusions. The 38-
year-old, also a black woman, died of congestive heart failure 
associated with anemia. A 19-year-old black man with sickle 
cell/p'^ -thalassemia is doing poorly with neurologic impairment 
due to a stroke, poor vision, hematuria, and hemoptysis. A 26-
year-old woman with sickle cell/P"'"-thalassemia had autoim-
mune hemolytic anemia and iliofemoral thrombosis. 
Ten of the 39 patients had a history of transfusions. Nine had 
received transfusions for anemia, and one patient had received a 
transfusion in preparation for hemia repair surgery. Five of the 
nine who received transfusions for anemia were P'^ -type and 
four were p^-type. No patient received a transfusion in the pe-
riod preceding hemoglobin electrophoretic study. 
Sickle cell/p*-thalassemia versus sickle cell/p^-thalassemia 
As previously described, 12 patients had sickle cell/p°-
thalassemia and 27 had sickle cell/p+-thalassemia. Laboratory 
and clinical results in these two groups are compared in Tables 1 
and 2. There were statistically significant differences in certain 
laboratory results. The mean hemoglobin level was lower and 
the mean level of hemoglobin S and mean reticulocyte count 
were higher in patients with sickle cell/p^-thalassemia. There 
was no significant difference in the frequency of different 
clinical manifestations except for cardiomegaly, which was 
more frequent in p°-thalassemia. 
Discussion 
In our study sickle cell/P"''-thalassemia was more common 
than sickle cell/p"-thalassemia. These findings are similar to 
those reported from Jamaica (4,7), probably because most of our 
patients were black, and blacks tend to carry the P"'' gene more 
frequently than the P" gene. A variety of clinical manifestations 
were observed in both groups of patients, including painful epi-
sodes, splenomegaly, joint pain with or without effusion, 
hepatomegaly, avascular necrosis of bone, cardiomegaly, and 
leg ulcers (4,6,8,9). When the group of patients with sickle 
cell/p''"-thalassemia was compared to the group with sickle 
cell/p"-thalassemia in terms of incidence of the different clinical 
manifestations, there was no statistically significant difference 
between the two groups except for cardiomegaly. Cardiomegaly 
was more frequent in the group with sickle cell/p^-thalassemia. 
Serjeant and Serjeant observed that the clinical course was more 
severe in patients with sickle cell/p^-thalassemia than in patients 
with sickle cell/P"'^ -thalassemia (7). Since our statistical com-
parison was based on the incidence of the various complications, 
we can neither discount nor support the conclusions of Serjeant 
and Serjeant. After seeing early deaths in two patients and 
severe clinical disease in a third patient with sickle 
cell/p^-thalassemia, we certainly recognize that sickle cell/p°-
thalassemia can be a severe disease in some patients. What we 
wish to emphasize is that frequent complications also can occur 
in patients with sickle cell/P'''-thalassemia. 
When laboratory data forthe two groups were compared, sev-
eral statistically significant differences were noted; the mean he-
moglobin S level and the reticulocyte count were higher and the 
mean hemoglobin level was lower in the group with sickle 
cell/p"-thalassemia. Our series included 12 younger patients, 
seven with sickle cell/P"''-thalassemia and five with sickle 
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Table 2 
Clinical Manifestations 
Sickle Cell/po-Thalassemia Sickle Cell/p'''-Thalassemia P-value 
Age 
No./Mean 12/25 27/30 
Range (years) 8-52 1-81 
Sex 
Males 3 14 
Females 9 13 
Race 
Blacks 12 24 
Whites 0 3 
Hepatomegaly 3 (25%) 4 (15%) NS 
Splenomegaly 5 (42%) 10 (37%) NS 
Joint pain 7 (58%) 11 (41%) NS 
Cardiomegaly 4 (33%) 0 (0%) 0.02 
Painful episodes 12 (100%) 20 (74%) NS 
Avascular necrosis of bone 0 (0%) 4 (15%) NS 
Cholecystectomy, gallstone 1 2 
Thrombophlebitis 2 1 
Dactylitis 1 1 
Retinopathy 1 2 
Other 
Died at young age 2 (1 
Transfusion 5 5* 
NS = not significant. 
cell/p^-thalassemia. When considering the influence that age 
might have had on the comparative analysis, ie, that more 
younger children in one group than the other may have affected 
the results of the comparison between the two groups of patients, 
our statistical analysis revealed that the age factor did not appear 
to influence the comparison. 
A fairly wide range of clinical complications was observed in 
patients with sickle cell/p"''-thalas!>emia and in those with sickle 
cell/p°-thalassemia. Clinical complications were almost as fre-
quent in patients with sickle cell/p+-thalassemia as in those with 
sickle cell/p"-thalassemia. With the exception of cardiomegaly, 
which was observed more frequently in the sickle cell/p"-
thalassemia group, there was no statistically significant dif-
ference between the two groups with respect to clinical com-
plications. Regarding the laboratory findings, patients with 
sickle cell/p^-thalassemia tended to have lower hemoglobins, 
higher levels of hemoglobin S, and higher reticulocyte counts 
than patients with sickle cell/p+-thalassemia. 
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